Skip to main content

Table 5 Blood products and reversal agents

From: Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists

 

Total (n = 346)

DOAC (n = 74)

Vitamin K antagonist (n = 272)

p

PCC (units), [median (IQR)]

2100

(1800-2400)

2000

(1700–3000)

2100

(1800-2400)

0.346

ECs given

48

(13.9)

15

(20.3)

33

(12.1)

0.073

Number of ECs

 1

23

(6.7)

6

(8.2)

17

(6.2)

 

 2

14

(4.1)

3

(4.1)

11

(4.0)

 

 3

7

(2.0)

4

(5.5)

3

(1.1)

 

 4

2

(0.6)

2

(2.7)

0

(0.0)

 

 5

2

(0.6)

0

(0.0)

2

(0.7)

0.014

Platelet concentrates

5

(1.4)

2

(2.7)

3

(1.1)

0.307

Fresh frozen plasma

19

(5.5)

6

(8.1)

13

(4.8)

0.265

Tranexamic acid

41

(11.8)

21

(28.4)

20

(7.4)

< 0.001

  1. Abbreviation: DOAC direct oral anticoagulants, ECs erythrocyte concentrates, IQR interquartile range, PCC prothrombin complex concentrate